ImmunityBio
IBRX
201 hedge funds and large institutions have $212M invested in ImmunityBio in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 71 increasing their positions, 41 reducing their positions, and 20 closing their positions.
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
73% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 41
11% more funds holding
Funds holding: 181 → 201 (+20)
1.46% more ownership
Funds ownership: 9.86% → 11.32% (+1.5%)
17% less call options, than puts
Call options by funds: $8.21M | Put options by funds: $9.86M
17% less capital invested
Capital invested by funds: $256M → $212M (-$43.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$12.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.5M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$11.7M |
| 4 |
Morgan Stanley
New York
|
+$7.33M |
| 5 |
BlackRock
New York
|
+$7.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$7.54M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$5.35M |
| 3 |
Millennium Management
New York
|
-$3.68M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$2.46M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.93M |
IBRX Hedge Fund Activity: Q4 2024 in Review
201 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2024, worth a combined $212M — down 17% from $256M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new IBRX positions and 20 closed out — a net gain of 24 holders — while 71 added to existing stakes and 41 trimmed.
The largest buyer was Woodline Partners, adding an estimated $12.5M. The largest seller was Bank of America, cutting an estimated $7.54M.
- 201 institutional investors held ImmunityBio (IBRX) as of Q4 2024, up from 181 in Q3 2024.
- Funds reported $212M of ImmunityBio stock for Q4 2024, down 17% quarter-over-quarter.
- 44 funds opened new ImmunityBio positions in Q4 2024 and 20 closed out, a net change of +24 holders.
- The largest ImmunityBio buyer in Q4 2024 was Woodline Partners, an estimated $12.5M added.
- The largest ImmunityBio seller in Q4 2024 was Bank of America, an estimated $7.54M sold.
Based on aggregated 13F filings for Q4 2024.